Don't have Telegram yet? Try it now!
https://magazine.pharmamkt.net/2018/12/05/genentechs-kadcyla-cut-the-risk-of-disease-recurring-by-half-compared-to-herceptin-in-people-with-her2-positive-early-breast-cancer-with-residual-disease-after-neoadjuvant-treatment/
Genentech’s Kadcyla Cut the Risk of Disease Recurring by Half Compared to Herceptin in People With HER2-Positive Early Breast Cancer With Residual Disease After Neoadjuvant Treatment